Bankinter | Lebrikizumab is a new treatment being developed for atopical dermatitis licensed by Eli Lilly to Almirall (ALM). In the third study in Phase III, it has shown to have had a significant improvement on the skin, relieving itching for people with this ailment when combined with topical corticosteroids. The study has met all the primary valuation criteria and the principal secondary ones, and has a security profile consistent…
I. Isardo (Link Securities) | Almirall (ALM) is a vertically integrated international pharmaceutical group which focuses on the purchase, production, storage, commercialisation and mediation in the sale of specialities and pharmaceutical products and of all types of raw materials used in the production of specialities and pharmaceutical products.
Bankinter | Almirall Q1’18 results were better than expected, with sales of 189.3 million euros (-0.1%); Ebitda of 58 million (+5.4%); Net Attributable Profit of 30.9 million (+57.1%) and net debt of 150 million euros. Finally, the DN/PN ratio has reached 7.4%.
This week Spanish pharmaceutical firm Almirall issued a profit-warning, citing the negative impact of its US business. The stock price has dropped 30% in two days.
MADRID | By Jaime Santisteban | Almirall, Campofrío and Sacyr are the most recommended values in the Spanish market, according the market consensus. Repsol turned down the offer to renew its two seats in the YPF ‘s board on Tuesday, and fixed its eyes in Norway instead. Also, unemployment in Spain reportedly dropped by 111,565 people in April. “Although this means a turning point in the Spanish economic recovery, the country remains in the deep well,” The Corner senior analyst Fernando G. Urbaneja explains.
Almirall said pharmacogenetics testing helps doctors to improve treatment efficacy, reduce side effects, and could lead to a cut down in healthcare system costs. Patient response to medicines is conditioned by genetics.